Cancer Detection Tool Saves Lives

The Large Urology Group Practice Association (LUGPA) released its prostate cancer screening guidelines in response to the recent PSA controversy, saying that data clearly demonstrates that are detecting prostate cancer earlier and thus saving lives.

The LUGPA’s position on PSA screening is:

  • Risks of prostate cancer screening must be uncoupled from risks of prostate cancer detection and treatment
  • PSA testing facilitates the early detection of prostate cancer, which results in a reduced risk of being diagnosed with or developing locally advanced and/or metastatic prostate cancer, and a reduction in prostate cancer-specific mortality
  • A baseline PSA level should be obtained in men in their 40s who have made an informed decision to pursue early detection of prostate cancer
  • Intervals for an individual’s prostate cancer screening should be adapted to: baseline PSA, prostate cancer risk factors (including African-American heritage and a family history of prostate cancer), and the potentially short preclinical timeline of aggressive cancers
  • PSA screening should be offered to men with a life expectancy of greater than or equal to 10 years, regardless of age
  • PSA testing should not be considered on its own, but rather as part of a multivariable approach to early prostate cancer detection

LUGPA is an organization advocating for integrated and coordinated urological care with more than 2,000 physician experts across the U.S. The association represents 121 large urology group practices in the United States, with more than 2,000 physicians who make up more than 20% of the nation’s practicing urologists.

International Prostate Cancer Research Group Receives Funding

The International Consortium for Prostate Cancer Genetics (ICPCG) received a grant for its important genetic research. Specifically, the ICPCG whole exome sequence project will receive funding. The results of this project could be incorporated in Dr. Catalona's SPORE (Specialized Program of Research Excellence) proposal to discover genetic variants associated with the aggressive types of prostate cancer that lead to the failure of active surveillance.

The ICPCG is a collaborative group conducting research on familial prostate cancer. The researchers in this group share a common interest in genetic susceptibility for prostate cancer. Dr. Catalona is a principal investigator of the Northwestern University site of the ICPCG.

Learn more about the ICPCG here.